The World initially fell to their knee’s in relief as the first press release on Moderna’s Covid-19 Vaccine clinical trials was released earlier this week.
“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg,” said
Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna.
“When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”
Shortly after this press release was released share prices in Moderna shot up over 27%.
The celebrations soon subsided though as heavy criticism came from the scientific community on the lack of details supplied on the study.
As Statsnews points out:
But was there good reason for so much enthusiasm? Several vaccine experts asked by STAT concluded that, based on the information made available by the Cambridge, Mass.-based company, there’s really no way to know how impressive — or not — the vaccine may be.
While Moderna blitzed the media, it revealed very little information — and most of what it did disclose were words, not data. That’s important: If you ask scientists to read a journal article, they will scour data tables, not corporate statements. With science, numbers speak much louder than words.
But another vital point which the press release failed to emphasize was the large number of serious injuries caused by the vaccine in the clinical trials. 3 of the 15 subjects in the high dose cohort (250 mcg) suffered a “serious adverse event” within 43 days of receiving Moderna’s jab. Thats 20% of the subjects.
The press release stated that the three volunteers developed Grade 3 systemic events, which is defined by the FDA as “Preventing daily activity and requiring medical intervention.”
The excitement really was all down to 8 of the volunteers producing neutralizing antibodies for the virus, which out of 45 people really is not overly impressive anyway. But lets pretend that is impressive for a moment, this stage in producing a coronavirus vaccine has never been the issue, the biggest hurdle to overcome is what happens when a subject comes into contact with the virus itself.
Previous attempts have always ended in disaster as the following video explains:
Let us know what you think about a potential vaccine for the COVID-19 virus, we’d love to hear your thoughts